Samrat Pharmachem (BOM:530125) Short-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530125 Samrat Pharmachem Ltd BOM:530125
68 GF Score
Price ₹227.15
GF Value ₹355.58
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Samrat Pharmachem Short-Term Debt?

Samrat Pharmachem BOM:530125 -1.88% 68 Short-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:530125 with a GF Score™ of 68/100 and a GF Value™ of ₹355.58 (Possible Value Trap). The stock has 4 warning signs investors should review.

Samrat Pharmachem's Short-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Samrat Pharmachem's quarterly Short-Term Debt increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹107 Mil) but then declined from Mar. 2026 (₹107 Mil) to Jun. 2026 (₹0 Mil).

Samrat Pharmachem's annual Short-Term Debt increased from Mar. 2024 (₹85 Mil) to Mar. 2025 (₹99 Mil) and increased from Mar. 2025 (₹99 Mil) to Mar. 2026 (₹107 Mil).

Samrat Pharmachem Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Samrat Pharmachem Short-Term Debt Related Terms

Samrat Pharmachem Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Samrat Pharmachem's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Samrat Pharmachem Short-Term Debt Chart

Samrat Pharmachem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.20 186.59 84.55 99.15 107.07

Samrat Pharmachem Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 109.49 0.00 107.07 0.00
BOM:530125
68GF Score
Samrat Pharmachem Ltd BOM:530125
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹0 Mil mean?
Samrat Pharmachem (BOM:530125) has a Short-Term Debt of ₹0 Mil as of Jun. 2026.
Is Samrat Pharmachem's Short-Term Debt too high?
Samrat Pharmachem's current Short-Term Debt is ₹0 Mil. Overall, Samrat Pharmachem has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Short-Term Debt compare to DOW?
Samrat Pharmachem's Short-Term Debt of ₹0 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Chemicals company?
A good Short-Term Debt depends on the Chemicals industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Samrat Pharmachem's current Short-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Possible Value Trap. The stock's GF Value™ is ₹355.58, compared to a current price of ₹227.15 — trading 36.1% below its estimated fair value. The current Short-Term Debt is ₹0 Mil. Samrat Pharmachem's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Short-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?

Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued. The current stock price of ₹227.15 is trading 36.1% below its estimated GF Value™ of ₹355.58. GuruFocus considers Samrat Pharmachem to be Possible Value Trap.

Key valuation signals for BOM:530125:

  • Short-Term Debt: ₹0 Mil
  • GF Value™: ₹355.58 vs. price of ₹227.15 (36.1% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Samrat Pharmachem Business Description

Address M. A. Road, 701/702, Business Square, Andheri (West), Mumbai, MH, IND, 400 058
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
68GF Score

Get the complete analysis for BOM:530125

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹227.15
Price
₹355.58
GF Value